About the manufacturer

Bioventus is an biologics and clinical therapies company spun out of Smith and Nephew in 2008. Smith and Nephew retain 49% ownership, the remainder owned by Essex Woodland Heath Ventures, a healthcare investment firm.

The company website states: Bioventus is the recognized leader in bone stimulation devices, and among the leading distributors of osteoarthritis injection treatments. Our active healing therapies work together with the body’s natural healing process, thereby shortening recovery time and potentially minimizing the overall cost of care. Our clinically proven solutions have helped many who suffer from fractures or osteoarthritic joint pain get their lives back on the right track.




Page 1 of 1
Show results per page
Sort By:  A-Z / Rating / Date
Bioventus LLC EXOGEN | Which Medical Device

No Editor Review

No Ratings


Exogen is an ultrasound-based system for the treatment of fracture non-union. Application for 20 minutes a day can accelerate bone healing, as confirmed by clinical studies. The device has NICE approval in the UK for the treatment of non-union (after 9 months) of long bones. A portal for the...

read full description

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.